Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients.
Gunnarsson R, Isaksson A, Mansouri M, Göransson H, Jansson M, Cahill N, Rasmussen M, Staaf J, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Juliusson G, Rosenquist R. Gunnarsson R, et al. Among authors: lundin j. Leukemia. 2010 Jan;24(1):211-5. doi: 10.1038/leu.2009.187. Epub 2009 Sep 10. Leukemia. 2010. PMID: 19741724 No abstract available.
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, Rasmussen M, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Geisler C, Juliusson G, Rosenquist R. Gunnarsson R, et al. Among authors: lundin j. Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5. Haematologica. 2011. PMID: 21546498 Free PMC article.
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation.
Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, Johansson E, Mellstedt H, Lundin J, Osterborg A. Karlsson C, et al. Among authors: lundin j. Leukemia. 2006 Dec;20(12):2204-7. doi: 10.1038/sj.leu.2404435. Epub 2006 Oct 19. Leukemia. 2006. PMID: 17051245 No abstract available.
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A. Winqvist M, et al. Among authors: lundin j. Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19. Haematologica. 2016. PMID: 27198718 Free PMC article.
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A; Swedish CLL Group. Winqvist M, et al. Among authors: lundin j. Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4. Haematologica. 2019. PMID: 30514799 Free PMC article. No abstract available.
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Sylvan SE, Rossmann E, Mozaffari F, Porwit A, Norin S, Karlsson C, Hansson L, Lundin J, Österborg A. Sylvan SE, et al. Among authors: lundin j. Br J Haematol. 2012 Dec;159(5):608-12. doi: 10.1111/bjh.12077. Epub 2012 Oct 9. Br J Haematol. 2012. PMID: 23043283 Free article. Clinical Trial. No abstract available.
302 results